Major depressive episodes

Active Ingredient: Vortioxetine

Indication for Vortioxetine

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Vortioxetine is indicated for the treatment of major depressive episodes in adults.

For this indication, competent medicine agencies globally authorize below treatments:

10 mg once daily as starting dose and thereafter, depending on individual patient response, 5-20 mg once daily for at least 6 months

For:

Dosage regimens

Oral, 10 milligrams vortioxetine, once daily. Afterwards, oral, between 5 milligrams vortioxetine and 20 milligrams vortioxetine, once daily.

Detailed description

The starting and recommended dose is 10 mg vortioxetine once daily in adults less than 65 years of age.

Depending on individual patient response, the dose may be increased to a maximum of 20 mg vortioxetine once daily or decreased to a minimum of 5 mg vortioxetine once daily.

After the depressive symptoms resolve, treatment for at least 6 months is recommended for consolidation of the antidepressive response.

Treatment discontinuation

A gradual reduction in dosage may be considered to avoid the occurrence of discontinuation symptoms. However, there is insufficient data to provide specific recommendations for a tapering schedule for patients treated with vortioxetine.

5 mg once daily and thereafter 5-10 mg once daily

For:

Dosage regimens

Oral, 5 milligrams vortioxetine, once daily. Afterwards, oral, between 5 milligrams vortioxetine and 10 milligrams vortioxetine, once daily.

Detailed description

The lowest effective dose of 5 mg vortioxetine once daily should always be used as the starting dose in patients ≥65 years of age. Caution is advised when treating patients ≥65 years of age with doses higher than 10 mg vortioxetine once daily for which data are limited.

Treatment discontinuation

A gradual reduction in dosage may be considered to avoid the occurrence of discontinuation symptoms. However, there is insufficient data to provide specific recommendations for a tapering schedule for patients treated with vortioxetine.

Active ingredient

Vortioxetine

Vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the 5-HT transporter, leading to modulation of neurotransmission in several systems, including predominantly the serotonin but probably also the norepinephrine, dopamine, histamine, acetylcholine, GABA and glutamate systems. This multimodal activity is considered responsible for the antidepressant and anxiolytic-like effects and the improvement of cognitive function, learning and memory observed with vortioxetine in animal studies.

Read more about Vortioxetine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.